These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17961046)

  • 1. Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition.
    Gupta V; Samuleson CG; Su S; Chen TC
    Neurosurg Focus; 2007; 23(4):E9. PubMed ID: 17961046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas.
    Gupta V; Su YS; Samuelson CG; Liebes LF; Chamberlain MC; Hofman FM; Schönthal AH; Chen TC
    J Neurosurg; 2007 Mar; 106(3):455-62. PubMed ID: 17367069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
    Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
    Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells.
    Al-Khalaf HH; Lach B; Allam A; Hassounah M; Alkhani A; Elkum N; Alrokayan SA; Aboussekhra A
    Brain Res; 2008 Jan; 1188():25-34. PubMed ID: 18048012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro.
    Ragel BT; Gillespie DL; Kushnir V; Polevaya N; Kelly D; Jensen RL
    Neurosurgery; 2006 Nov; 59(5):1109-20; discussion 1120-1. PubMed ID: 17143245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.
    Horak P; Wöhrer A; Hassler M; Hainfellner J; Preusser M; Marosi C
    J Neurooncol; 2012 Sep; 109(2):323-30. PubMed ID: 22610940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
    Schrell UM; Rittig MG; Anders M; Kiesewetter F; Marschalek R; Koch UH; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):845-52. PubMed ID: 9126901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.
    Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
    Cancer; 2007 Feb; 109(3):588-97. PubMed ID: 17177201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.
    Kondraganti S; Gondi CS; Gujrati M; McCutcheon I; Dinh DH; Rao JS; Olivero WC
    Int J Oncol; 2006 Jul; 29(1):25-32. PubMed ID: 16773181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.
    Skibinski CG; Williamson T; Riggins GJ
    J Neurooncol; 2018 Dec; 140(3):529-538. PubMed ID: 30414098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo.
    Matsuda Y; Kawamoto K; Kiya K; Kurisu K; Sugiyama K; Uozumi T
    J Neurosurg; 1994 Mar; 80(3):527-34. PubMed ID: 8113866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells.
    Kliese N; Gobrecht P; Pachow D; Andrae N; Wilisch-Neumann A; Kirches E; Riek-Burchardt M; Angenstein F; Reifenberger G; Riemenschneider MJ; Meese E; Panayotova-Dimitrova D; Gutmann DH; Mawrin C
    Oncogene; 2013 Sep; 32(39):4712-20. PubMed ID: 23108408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
    Reardon DA; Norden AD; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Sampson JH; Gururangan S; Peters KB; McLendon RE; Norfleet JA; Lipp ES; Drappatz J; Wen PY; Friedman HS
    J Neurooncol; 2012 Jan; 106(2):409-15. PubMed ID: 21938530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
    Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTORC1 inhibitors suppress meningioma growth in mouse models.
    Pachow D; Andrae N; Kliese N; Angenstein F; Stork O; Wilisch-Neumann A; Kirches E; Mawrin C
    Clin Cancer Res; 2013 Mar; 19(5):1180-9. PubMed ID: 23406776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
    Jiang C; Song T; Li J; Ao F; Gong X; Lu Y; Zhang C; Chen L; Liu Y; He H; Huang O
    Mol Neurobiol; 2017 Jan; 54(1):779-787. PubMed ID: 27021020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
    Palmberg E; Johnsen JI; Paulsson J; Gleissman H; Wickström M; Edgren M; Ostman A; Kogner P; Lindskog M
    Int J Cancer; 2009 Mar; 124(5):1227-34. PubMed ID: 19058199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
    Wilisch-Neumann A; Kliese N; Pachow D; Schneider T; Warnke JP; Braunsdorf WE; Böhmer FD; Hass P; Pasemann D; Helbing C; Kirches E; Mawrin C
    Clin Cancer Res; 2013 Oct; 19(19):5402-12. PubMed ID: 23948974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application.
    Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
    J Neurosurg; 2005 Sep; 103(3):508-17. PubMed ID: 16235684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.